Within the last two decades, SARS and MERS coronaviruses emerged as global health concerns causing severe acute respiratory syndromes. In December 2019, a novel coronavirus (SARS-CoV-2) was identified in Wuhan, Hubei province in China. The SARS-CoV genome encodes several proteases including papain-like protease (PL2PRO; PLPro); this key enzyme along with 3CL-protease drives the early stage of infection by processing a large viral polypeptide into functional enzymes. SARS-CoV-2 PLPro shares 82% in protein sequence identity with PLPro from SARS-CoV. The SARS-CoV-2 PLPro was shown to have a deubiquitinating activity. Subsequently, it was shown that PLPro is also a deISGylase. PLPro cleaves ISG15 and Ubiquitin from synthetic substrates with high and low efficiency, respectively. PLPro represents an antiviral drug target for counteracting SARS-CoV-2 infections.
|Molecular Weight||62 kDa|
|Formulation||50 mM Tris-HCl pH 8.5, 150 mM NaCl, 1 mM DTT, 10% glycerol|
|Storage||-80°C, avoid freeze/thaw cycles|